What we do

We bring patients across North America, MENA and Europe a broad range of generic, specialty and branded pharmaceutical products.

We have 3 distinct businesses that enable us to create high-quality medicines and make them accessible to those who need them.

We have 29 manufacturing plants, eight R&D centres and c.9,100 employees worldwide, manufacturing and supplying over 760 products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Learn more about what we do


We are the third largest supplier of generic injectables in the US [1]. We supply hospitals across our markets with generic injectable products, supported by our manufacturing facilities in the US, Europe and MENA.


We are the second largest pharmaceutical company in MENA. We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

We supply oral and other non-injectable generic and specialty branded products to the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.
Our business in numbers
$ 1,141 m Injectables 2022 revenue
$ 691 m Branded 2022 revenue
$ 672 m Generic 2022 revenue

1. IQVIA MAT May 2023, generic injectables by volume (excluding branded generics and Becton Dickinson).
2.Based on internal analysis by Hikma using IQVIA MIDASĀ® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Number of products as of February 2024.